

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces Results of REGN-COV 2066 Study for Ronapreve for the Treatment in Patients Hospitalized with COVID-19

TOKYO, September 30, 2021 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release today regarding results of REGN-COV 2066 study for the anti-SARS-CoV-2 monoclonal antibody Ronapreve™ [generic name: casirivimab (genetical recombination)/imdevimab (genetical recombination)] for the treatment in adult patients hospitalized with COVID-19.

Please refer to the link below for details of the press release:

Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19

<https://www.roche.com/media/releases/med-cor-2021-09-30.htm>

Trademarks used or mentioned in this release are protected by laws.

###